Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
e Department of Gastroenterology, University of Maryland School of Medicine, MD, USA (Hassan Ghoz) Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with gastrointestinal (GI) adverse effects, but real-world evidence about their incidence in patients with functional GI disorders is limited
Avoid ibuprofen and aspirin for 48 hours (bleeding risk) Days 27 Resume normal activities including exercise from day 2 Effects start to appear from day 3, becoming more noticeable through day 57 Bruising at injection points typically resolves by day 5 Continue arnica tablets if started before treatment Dont undergo vigorous facial massage or aggressive facials Days 714 Effect continues to develop
Currently, GLP-1 patches are not licensed or available for prescribing in the UK
This is because: GLP-1 agonists: Slow gastric emptying, enhance insulin secretion, regulate hepatic glucose Amylin agonists: Suppress appetite centrally, slow gastric emptying via distinct pathways Together: Complementary mechanisms produce additive/synergistic effects on weight loss Cagrilintide Monotherapy Trials Initial clinical development focused on establishing the safety, tolerability, and efficacy of cagrilintide as a standalone therapy for weight management
